PMCID: PMC3404108This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Abrams, EJ

Cotton, M

Gibb, DM

Mulenga, V

Musoke, P

Penazzato, M

Prendergast, AJ

PLoS Medicine

English

PubMed

CITATION: Prendergast, A. J. et al. 2012. Treatment of young children with HIV infection : using evidence to inform policymakers. PLoS Medicine, 9(7): e1001273, doi:10.1371/journal.pmed.1001273.The original publication is available at http://journals.plos.org/plosmedicineNo abstract available.http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001273Publisher's versio

Prendergast, A. J.

Penazzato, M.

Cotton, M. F.

Musoke, P.

Mulenga, V.

Abrams, E. J.

Gibb, D. M.

Stellenbosch University SUNScholar Repository

Treatment of young children with HIV infection : using evidence to inform policymakers

Andrew J. Prendergast

Martina Penazzato

Mark Cotton

Philippa Musoke

Veronica Mulenga

Elaine J. Abrams

Diana M. Gibb

Crossref

Treatment of Young Children with HIV Infection: Using Evidence to Inform Policymakers

UCL Discovery

Treatment of young children with HIV infection: Using evidence to inform policymakers

Prendergast Andrew J.

Penazzato Martina

Cotton Mark

Musoke Philippa

Mulenga Veronica

Abrams Elaine J.

Gibb Diana M.

Public Library of Science (PLOS)

Andrew J Prendergast

Elaine J Abrams

Diana M Gibb

Directory of Open Access Journals

Treatment of young children with HIV infection: using evidence to inform policymakers.

Queen Mary Research Online

A trial of three antiretroviral regimens in HIV-1-infected children.

Antiretroviral drugs in the cupboard are not enough: the impact of health systems’ performance on mother-to-child transmission of HIV.

Antiretroviral therapies in women after single-dose nevirapine exposure.

Antiretroviral treatment for children with peripartum nevirapine exposure.

Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.

Available: http://www.unaids.org/en/ resources/publications/2011/.

Countdown To Zero: global plan towards elimination of new HIV infections among children by 2015 and keeping their mothers alive.

Early antiretroviral therapy and mortality among HIV-infected infants.

Early ART followed by interruption is safe and is associated with better outcomes than deferred ART

Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1.

Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.

Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. Cochrane Database Syst Rev.

Evidence to Inform Policymakers Andrew J.

First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

Global HIV/AIDS response: progress report

Mortality of infected and uninfected infants born to HIVinfected mothers in Africa: a pooled analysis.

NVP- vs LPV/rbased ART among HIV+ infants in resourcelimited settings:

Organization

Pediatric HIV–a neglected disease?

Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.

Response to antiretroviral therapy after a single, peripartum dose of nevirapine.

Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.

Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination ‘‘baby pills’’ in Zambia: a randomized controlled trial.

Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a proteaseinhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. Epub ahead of print 15

Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort.

The cost of early vs. deferred paediatric antiretroviral treatment in South Africa - a comparative economic analysis of the first year of the CHER trial.

The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord (2011) Early antiretroviral therapy in HIV-1 infected infants in Europe, 1996–2008: treatment response and duration of first line regimens.

The treatment 2.0 framework for action: catalysing the next phase of treatment, care and support. Available: http://data.unaids.org/ pub/Out look/2010/20100713_out look_ treatment2_0_en.pdf. Accessed on 24

Treatment interruption in infants following 24 months of empiric ART:

Twin preterm neonates with Box 2. Requirements for Antiretroviral Drugs

https://scholar.sun.ac.za:443/bitstream/handle/10019.1/82008/prendergast_treatment_2012.PDF?sequence=1&isAllowed=y

Treatment of Young Children with HIV Infection: Using Evidence to Inform Policymakers

Abstract

Similar works

Full text

Available Versions